Form 4: Nuvation Bio CSO Sells Shares After Option Exercise
Insider Transaction Report
Nuvation Bio's Chief Scientific Officer, Gary Hattersley, exercised stock options and subsequently sold a total of 369,051 Class A Common Stock shares.
Summary
- Gary Hattersley, Chief Scientific Officer of Nuvation Bio Inc. (NUVB), reported transactions on November 20, 2025.
- He exercised options to acquire 69,051 shares of Class A Common Stock at an exercise price of $1.74 per share.
- Concurrently, he sold all 69,051 shares at a weighted-average price of $7.227 per share, with individual sales ranging from $7.15 to $7.43.
- He also exercised options to acquire 300,000 shares of Class A Common Stock at an exercise price of $1.94 per share.
- Immediately after, he sold all 300,000 shares at a weighted-average price of $7.227 per share, with individual sales ranging from $7.15 to $7.43.
- Following these transactions, the reporting person beneficially owns 0 shares of Class A Common Stock directly from these specific reported transactions.
- He retains 229,884 stock options with an exercise price of $1.74 and 200,000 stock options with an exercise price of $1.94.
Sentiment
Score: 4
Explanation: While the insider realized a significant profit, the sale of a substantial number of shares by a Chief Scientific Officer could be viewed with slight caution by investors, even if it's for personal diversification or tax planning. The profit itself is positive for the individual, but the act of selling is generally not a strong positive signal for the stock.
Positives
- The Chief Scientific Officer realized a significant gain by exercising options at low prices ($1.74 and $1.94) and selling shares at a substantially higher weighted-average price of $7.227.
Negatives
- An insider sale, particularly by a Chief Scientific Officer, could be interpreted by the market as a signal, potentially indicating a lack of confidence or a desire for personal diversification.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: May interpret the insider sale as a signal, potentially influencing sentiment regarding the company's future prospects or management's confidence.
Key Dates
| Date | Description |
|---|---|
| 07/01/2020 | Start of vesting for 69,051 stock options (25% vested, then monthly over three years). |
| 02/28/2023 | One-year anniversary for vesting of 300,000 stock options (25% vested, then monthly over 36 months). |
| 11/20/2025 | Date of stock option exercises and subsequent sales of Class A Common Stock. |
| 11/24/2025 | Signature date of the reporting person's attorney-in-fact. |
| 01/21/2030 | Expiration date for 69,051 stock options. |
| 02/27/2033 | Expiration date for 300,000 stock options. |
Recommendation
holdThe filing reports an insider sale by the Chief Scientific Officer, Gary Hattersley, who exercised options and immediately sold a significant number of shares for a substantial profit. While the profit realized by the insider is notable, the act of selling by a key executive can sometimes be perceived negatively by the market. However, without additional context on the company's performance, future outlook, or the insider's personal financial planning, a definitive 'buy' or 'sell' recommendation based solely on this Form 4 is premature. It warrants a 'hold' recommendation, suggesting investors monitor future filings and company news for further insights into Nuvation Bio's prospects and management's confidence.
Keywords
Nuvation Bio, NUVB, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Gary Hattersley, Chief Scientific Officer, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.